{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:20:28Z","timestamp":1721348428259},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.7759\/cureus.64774","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:05:36Z","timestamp":1721275536000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Use of Abemaciclib Leading to Breathlessness and Demise: A Case Report"],"prefix":"10.7759","author":[{"given":"Jonathan T","family":"Burrows","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","article-title":"Breast","year":"2020","unstructured":"Breast. Robbins Basic Pathology. Kumar V, Abbas AK, Aster JC (ed). Elsevier, Philadelphia (PA); 2020. 10:"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9751","article-title":"Estrogen and progesterone receptor expression in breast carcinoma and its association with clinicopathological variables among the Pakistani population","volume":"12","author":"Sohail SK","year":"2020","unstructured":"Sohail SK, Sarfraz R, Imran M, Kamran M, Qamar S. Estrogen and progesterone receptor expression in breast carcinoma and its association with clinicopathological variables among the Pakistani population. Cureus. 2020, 12:e9751. 10.7759\/cureus.9751","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon DJ","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987, 235:177-82. 10.1126\/science.3798106","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2018.02.006","article-title":"Overview of breast cancer therapy","volume":"13","author":"Moo TA","year":"2018","unstructured":"Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018, 13:339-54. 10.1016\/j.cpet.2018.02.006","journal-title":"PET Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada SA","year":"2013","unstructured":"Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer. 2013, 108:1560-5. 10.1038\/bjc.2013.117","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid P","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, et al.. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21:44-59. 10.1016\/S1470-2045(19)30689-8","journal-title":"Lancet Oncol"},{"key":"ref8","unstructured":"FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. (2021). Accessed. July 1, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-locally-...."},{"key":"ref9","unstructured":"FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. (2023). Accessed. July 1, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-tripl...."},{"key":"ref10","unstructured":"FDA D.I.S.C.O. Burst Edition. FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer. (2023). Accessed: July 1, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-verzenio-abemacic...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer","volume":"12","author":"Corona SP","year":"2018","unstructured":"Corona SP, Generali D. Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer. Drug Des Devel Ther. 2018, 12:321-30. 10.2147\/DDDT.S137783","journal-title":"Drug Des Devel Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby S","year":"2011","unstructured":"Darby S, McGale P, Correa C, et al.. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011, 378:1707-16. 10.1016\/S0140-6736(11)61629-2","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.07.017","article-title":"Quantification of residual risk of relapse in breast cancer patients optimally treated","volume":"22","author":"Dieci MV","year":"2013","unstructured":"Dieci MV, Arnedos M, Delaloge S, Andre F. Quantification of residual risk of relapse in breast cancer patients optimally treated. Breast. 2013, 22:S92-5. 10.1016\/j.breast.2013.07.017","journal-title":"Breast"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation","volume":"10","author":"Zhu S","year":"2020","unstructured":"Zhu S, Fu Y, Zhu B, Zhang B, Wang J. Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation. Front Oncol. 2020, 10:1785. 10.3389\/fonc.2020.01785","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley WT","year":"2021","unstructured":"Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest. 2021, 160:731-42. 10.1016\/j.chest.2021.02.032","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.993753","article-title":"The potential role of PD0332991 (palbociclib) in the treatment of multiple myeloma","volume":"24","author":"Altenburg JD","year":"2015","unstructured":"Altenburg JD, Farag SS. The potential role of PD0332991 (palbociclib) in the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015, 24:261-71. 10.1517\/13543784.2015.993753","journal-title":"Expert Opin Investig Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2682-1","article-title":"The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material","volume":"38","author":"Ferguson ND","year":"2012","unstructured":"Ferguson ND, Fan E, Camporota L, et al.. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012, 38:1573-82. 10.1007\/s00134-012-2682-1","journal-title":"Intensive Care Med"},{"key":"ref19","unstructured":"Oxygen delivery devices. (2024). Accessed. July 1, 2024: https:\/\/critcareedu.com.au\/oxygen-delivery-devices\/."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien V","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023, 9:7. 10.1038\/s41523-023-00508-3","journal-title":"NPJ Breast Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/274817-chronic-use-of-abemaciclib-leading-to-breathlessness-and-demise-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:05:42Z","timestamp":1721275542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/274817-chronic-use-of-abemaciclib-leading-to-breathlessness-and-demise-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.64774","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}